Major bleeding and thromboembolic complications associated with antithrombotic treatment in patients with atrial fibrillation/flutter and incident cancer
Background: Anticoagulant management of patients with atrial fibrillation with active cancer is complex because cancer increases the risk of thrombosis as well as bleeding. Previous studies have investigated the impact of any type of cancer, while outcomes may differ per specific type. We performed...
Saved in:
| Main Authors: | Gordon Chu, Nienke van Rein, Menno V Huisman, Lars Pedersen, Henrik T. Sørensen, Suzanne C. Cannegieter, Frederikus A. Klok |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Research and Practice in Thrombosis and Haemostasis |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2475037925000214 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Major bleeding and thromboembolism risks of antithrombotic treatment in patients with incident atrial fibrillation/flutter and a history of cancer
by: Nienke van Rein, et al.
Published: (2025-02-01) -
THE ENDOVASCULAR PREVENTION OF THROMBOEMBOLISM IN ATRIAL FIBRILLATION
by: Rami N. Al-Ayyubi, et al.
Published: (2018-12-01) -
NOVEL ANTICOAGULANTS FOR THROMBOEMBOLIC COMPLICATIONS PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
by: D. A. Itkin, et al.
Published: (2015-02-01) -
Risk of recurrence and bleeding in patients with cancer‐associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study
by: Mette Søgaard, et al.
Published: (2019-03-01) -
Efficacy and safety of left atrial appendage closure in patients with atrial fibrillation and high thromboembolic and bleeding risk
by: D. V. Pevzner, et al.
Published: (2022-09-01)